Welcome to our dedicated page for Adma Biologics SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ADMA Biologics' SEC filings document its specialty biologics business through Form 8-K reports on operating and financial results, FDA-related disclosures for ASCENIV, Regulation FD materials and other material-event updates. These records include disclosures tied to product revenue trends, immune globulin market conditions, commercial distribution, plasma collection and biomanufacturing operations.
ADMA's definitive proxy materials cover annual meeting matters, board and governance proposals, voting procedures and executive compensation. Its current reports also document executive transitions, related agreements, capital-structure matters, share-repurchase activity and risk-oriented product disclosures associated with immune globulin products.
ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina reported new equity awards. On February 9, 2026, she received 91,631 shares of common stock as restricted stock units at $0 per share and a stock option for 144,230 shares with a $16.37 exercise price.
The RSUs vest quarterly on each annual anniversary of the grant date over four years under the 2022 Equity Compensation Plan, subject to continued service. The option vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly until becoming fully vested on February 9, 2030. Following these grants, she beneficially owns 580,321 shares of common stock and 144,230 stock options, all held directly.
ADMA Biologics President and CEO Adam S. Grossman reported new equity awards. On February 9, 2026, he acquired 282,529 shares of common stock in the form of restricted stock units granted at $0 and 444,711 stock options with a $16.37 exercise price.
The RSUs vest quarterly over four years under ADMA’s 2022 Equity Compensation Plan, subject to his continued service. The options also vest over four years, with 25% vesting on the one‑year anniversary and the remaining 75% vesting monthly until fully vested on February 9, 2030. After these awards, he directly beneficially owns 2,290,379 shares of common stock and also has indirect ownership of additional ADMA shares through Areth, LLC and Hariden, LLC.
ADMA Biologics director Young Kwon reported new equity awards. On February 9, 2026, he received 10,690 shares of common stock in the form of restricted stock units granted at $0, which vest in two equal installments over one year, subject to continued service. He also received a stock option to buy 17,730 shares of common stock at an exercise price of $16.37 per share, vesting in twelve equal monthly installments and becoming fully vested on February 9, 2027. After these awards, he directly holds 263,020 shares of common stock, including RSUs, and 17,730 stock options.
ADMA Biologics director Alison C. Finger received new equity awards in the form of restricted stock units (RSUs) and stock options on February 9, 2026. She acquired 10,690 RSUs at a price of $0, bringing her directly held common stock and RSU-related holdings to 45,619 shares.
The 10,690 RSUs vest in two equal installments on the six- and 12‑month anniversaries of the grant date, becoming fully vested after one year, subject to continued service. She was also granted stock options for 17,730 shares of common stock at an exercise price of $16.37, which vest in twelve equal monthly installments over one year.
ADMA Biologics director Eduardo Rene Salas reported new equity awards. On February 9, 2026, he acquired 10,690 shares of common stock in the form of restricted stock units, granted at a price of $0, which will vest in two equal installments over one year.
Following this grant, he beneficially owned 21,579 shares of common stock, including previously granted RSUs and 5,444 owned shares. He was also granted stock options to buy 17,730 shares of common stock at an exercise price of $16.37, vesting in twelve equal monthly installments and becoming fully vested one year from the grant date.
ADMA Biologics director Lawrence P. Guiheen reported new equity awards and updated his holdings. On February 9, 2026, he received 10,690 restricted stock units at $0 and a stock option for 17,730 shares at an exercise price of $16.37.
The RSUs vest in two equal installments on the six- and 12‑month anniversaries of the grant date, becoming fully vested on February 9, 2027, subject to continued service. The options vest in twelve equal monthly installments over one year. After these grants, he directly beneficially owns 105,520 shares of common stock and indirectly holds 50,990 shares through the Lawrence P Guiheen Irrevocable Trust 1.
ADMA Biologics director Steve Elms reported new equity awards. On February 9, 2026, he acquired 10,690 restricted stock units of common stock at $0 and a stock option to buy 17,730 shares at $16.37, also valued at $0 on grant.
After these awards, he directly holds 98,020 shares of common stock (including RSUs) and 17,730 stock options. The filing also notes 2,031,730 shares of common stock held indirectly through Aisling Capital II LP, where he may be deemed a beneficial owner but disclaims beneficial ownership except for his pecuniary interest.
ADMA Biologics, Inc. filed a current report describing that it has issued a press release with preliminary, unaudited full year 2025 revenue figures and a broader business update. The company notes that these results are subject to completion of its accounting and annual audit procedures and may change once the audit is finished, so they should be viewed as early estimates rather than final numbers.
ADMA is also making available a Corporate Presentation it expects to use in meetings with potential investors, strategic partners, industry analysts and others. Both the press release and the presentation are provided as exhibits to the report and are described as being furnished, not filed, which means they are not automatically incorporated into other securities law filings unless specifically referenced.
ADMA Biologics’ president and CEO reported option exercises and stock sales in company shares. On 12/15/2025, he exercised a stock option covering 15,000 shares of common stock at an exercise price of $5.40 per share and, on the same date, sold 15,000 shares and a separate 6,000-share block at a sale price of $19.79 per share. The transactions were carried out under a Rule 10b5-1 trading plan entered into on December 5, 2024 with Fidelity Brokerage Services LLC. Following these trades, he directly holds 2,007,850 shares of ADMA Biologics common stock, along with indirect holdings of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, and continues to hold 720,950 stock options.
ADMA Biologics (ADMA) reported insider equity activity by its President, CEO and Director, Adam S. Grossman. On 11/19/2025, he exercised a stock option to acquire 15,000 shares of common stock at an exercise price of $5.40 per share, then sold 15,000 shares and an additional 6,000 shares of common stock at a sale price of $16.00 per share. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on December 5, 2024. Following these transactions, he directly owned 2,013,850 shares of common stock, with additional indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, along with 735,950 stock options and multiple tranches of unvested RSUs that vest over four-year schedules.